Company intelligence / Profile preview
Shanghai Ennovabio Pharmaceuticals
Shanghai, Shanghai, Chinaennovabio.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
EnnovaBio has several programs in clinical development. Lead assets include ENB‑106 and ENN‑0403 for diabetic eye diseases in Phase 2 trials. Other pipeline assets are in Phase 1 or IND stage for metabolic and autoimmune/inflammatory indications. The company leverages a proprietary systems biology platform to identify novel targets and develop small molecule therapies focused on immunology and metabolic complications prevalent in China. No late-stage or commercialized products as of May 2025.
- Therapeutic areas
- GastroenterologyDermatologyOphthalmologyNephrology
- Modalities
- Small molecule drugssiRNA
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Zhangjiang Leading Venture Capital among investors/partners
Beyond the preview
Go deeper on Shanghai Ennovabio Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shanghai Ennovabio Pharmaceuticals.